Home » Healthcare » Pharmaceuticals » Thyroid Gland Disorders Treatment Market

Thyroid Gland Disorders Treatment Market By Treatments (Hypothyroidism, Hyperthyroidism) – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2023

Published: | Report ID: 11293 | Report Format : PDF

Market Insights

The thyroid gland disorders treatment market is propelling due to factors such as the rise in the patient base suffering from thyroid disorders, the rising geriatric population, and the consistent introduction of innovative and novel therapeutics by market players, leading to the growth of the market.

Asia Pacific is expected to be the fastest-growing market in the thyroid gland disorder treatment market due to a large patient base leading to large consumption of generic drugs for the treatment of thyroid diseases, especially in countries such as China, India, and Japan. Moreover, the growing research and development in the drug discovery of thyroid gland disorders would further drive the market during the forecast period.

The “Thyroid Gland Disorders Treatment Market: Growth, Share, Opportunities, and Competitive Analysis, 2016–2023” offers strategic insights into the overall thyroid gland disorders treatment market, along with the market size and estimates for the duration of 2016–2023. The said research study covers an in-depth analysis of multiple market segments based on the type of treatment and different geographical regions.

The treatment type segments studied for analyzing the overall thyroid gland disorders treatment market are hypothyroidism and hyperthyroidism treatment. Hypothyroidism treatment includes drugs such as levothyroxine and liothyronine, while hyperthyroidism treatment includes drugs such as imidazole and propanil. To help strategic decision-makers, the report also includes competitive profiling of the leading players in the thyroid gland disorders treatment market, attractive investment propositions, and market positioning of key manufacturers. Other in-depth analysis provided in the report includes:

Geographically, the thyroid gland disorders treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2013–2023. Market growth rates for the forecast period 2016–2023 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global thyroid gland disorders treatment market. Tools such as the market positioning of key players and an attractive investment proposition provide the readers with insights into the competitive scenario of the global thyroid gland disorders treatment market. This report concludes with a company profiles section that highlights major information about the key players engaged in the thyroid gland disorders market. In-depth competitive environment analysis and historical years (2013 and 2014) of market size data are also provided in the report.

Thus, the research study provides a holistic view of the global thyroid gland disorders treatment market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the factors mentioned above.

Based on the type of treatment, the global thyroid gland disorders treatment market is segmented as follows:

  • Hypothyroidism
  • Levothyroxine
  • Liothyronine
  • Hyperthyroidism
  • Imidazole
  • Tropical

Thyroid gland disorder is characterized by underactive or overactive production of thyroid hormones (T3 and T4), termed hypothyroidism or hyperthyroidism, respectively. Thyroid disorders can range from a small, harmless goiter (an enlarged gland) that needs no treatment to life-threatening cancer. The most common thyroid problems involve abnormal production of thyroid hormones. Too much thyroid hormone results in a condition known as hyperthyroidism. Insufficient hormone production leads to hypothyroidism. Thyroid gland disorders affect around 5% to 10% of the human population globally. Women are more susceptible to thyroid problems.

More than 12 percent of the U.S. population will develop a thyroid condition during their lifetime. An estimated 20 million Americans have some form of thyroid disease. The thyroid gland disorders treatment market is segmented into hypothyroidism and hyperthyroidism treatment. Hypothyroidism treatment includes drugs such as levothyroxine and liothyronine, while hyperthyroidism treatment includes drugs such as imidazole and propanil. The thyroid gland disorders treatment market is propelling due to factors such as the rise in the patient base suffering from thyroid disorders, the rising geriatric population, and the consistent introduction of innovative and novel therapeutics by market players, leading to the growth of the market.

For this study, the global thyroid gland disorder treatment market is categorized as follows:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

The geographical segmentation of the global market for thyroid gland disorders treatment comprises North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. In the base year of 2015, North America accounted for the largest market in the thyroid gland disorders treatment market due to the rising number of patients suffering from thyroid diseases in the U.S. According to the American Thyroid Association (ASA), more than 12% of the U.S. population will develop a thyroid condition during their lifetime, and an estimated 20 million Americans have some form of thyroid disease.

Moreover, mandatory screening of newborns for congenital hypothyroidism and cost-effective methods to detect thyroid cancer by screening would further expand the thyroid gland disorders treatment market. Rising patient populations in Europe are expected to drive the European thyroid gland disorders treatment market during the forecast period. Asia Pacific is expected to be the fastest-growing market in the thyroid gland disorder treatment market due to a large patient base leading to large consumption of generic drugs for the treatment of thyroid diseases, especially in countries such as China, India, and Japan. Moreover, the growing research and development in the drug discovery of thyroid gland disorders would further drive the market during the forecast period.

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Thyroid Gland Disorders Treatment Market Portaiture
2.2 Global Thyroid Gland Disorders Treatment Market, by Treatment, 2015 (USD Mn)
2.3 Thyroid Gland Disorders Treatment Market Share, by Geography, 2015 (Value %)

Chapter 3 Thyroid Gland Disorders Treatment : Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.2 Epidemiology of Thyroid Disorders
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.2 Rising Geriatric Population
3.3.1.3 Government Initiative
3.3.2 Challenges
3.3.2.1 Rising Consumption of Generic Drugs
3.3.3 Opportunities
3.3.3.1 Technological Advancements
3.4 Regulatory Framework
3.5 Attractive Investment Proposition
3.6 Competitive Analysis
3.5.1 Market Share Analysis By Key Players, 2015 (Value %)

Chapter 4 Thyroid Gland Disorders Treatment Market, by Treatments
4.1 Preface
4.2 Hypothyroidism
4.2.1 Levothyroxine
4.2.2 Liothyronine
4.3 Hyperthyroidism
4.3.1 Imidazole
4.3.1 Propacil

Chapter 5 Thyroid Gland Disorders Treatment Market, By Geography
5.1 Overview
5.2 North America
5.2.1. U.S.
5.2.2. Canada
5.3 Europe
5.3.1. U.K.
5.3.2. Germany
5.3.3. Rest of Europe
5.4 Asia Pacific
5.4.1. Japan
5.4.2. China
5.4.3. Rest of Asia Pacific
5.4 Latin America
5.5 Middle East and Africa

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Abbvie, Inc.
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Allergan plc.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 GlaxoSmithKline plc
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Merck KGaA
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Mylan N.V.
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Novartis AG
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 Lannett Company Inc.
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Sonofi
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Takeda Pharmaceutical Company Ltd
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
7.11 Other Notable Players

List of Figures

FIG. 1 Global Thyroid Gland Disoreders Treatment Market, by Treatment, 2015 (USD Mn)
FIG. 2 Global Thyroid Gland Disoreders Treatment Market Share, by Geography, 2015 (Value %)
FIG. 3 Attractive Investment Proposition, Global Thyroid Gland Disoreders Treatment Market, 2015
FIG. 4 Market Share Analysis By Key Players, 2015 (Value %)
FIG. 5 Global Hypothyroidsm Market Revenue, by Drug, 2013 – 2023 (USD Mn)
FIG. 6 Global Levothyroxine Market Revenue, 2013 – 2023 (USD Mn)
FIG. 7 Global Liothyronine Market Revenue, 2013 – 2023 (USD Mn)
FIG. 7 Global Hyperthyroidm Market Revenue, by Drugs, 2013 – 2023 (USD Mn)
FIG. 8 Global Imidazole Market Revenue, 2013 – 2023 (USD Mn)
FIG. 9 Global Propacil Market Revenue, 2013 – 2023 (USD Mn)

List of Tables

TABLE 1 Global Thyroid Gland Disoreders Treatment Revenue, by Treatment Type, 2013 – 2023 (USD Mn)
TABLE 2 Global Thyroid Gland Disoreders Treatment Market Revenue, by Geography, 2013 – 2023 (USD Mn)
TABLE 3 North America Thyroid Gland Disoreders Treatment Market Revenue, by Country, 2013 – 2023 (USD Mn)
TABLE 4 Europe Thyroid Gland Disoreders Treatment Market Revenue, by Country, 2013 – 2023 (USD Mn)
TABLE 5 Asia – Pacific Thyroid Gland Disoreders Treatment Market Revenue, by Country, 2013 – 2023 (USD Mn)
TABLE 6 Latin America Thyroid Gland Disoreders Treatment Market Revenue, by Regions, 2013 – 2023 (USD Mn)

Frequently Asked Questions:

What is the size of Thyroid Gland Disorders Treatment Market?

The market for Thyroid Gland Disorders Treatment Market is expected to reach USD 2.5 Mn By 2023.

What is the Thyroid Gland Disorders Treatment Market CAGR?

The Thyroid Gland Disorders Treatment Market is expected to see significant CAGR growth over the coming years, at 3.3%.

What is the Forecast period considered for Thyroid Gland Disorders Treatment Market?

The report is forecasted from 2016 to 2023.

What is the base year considered for Thyroid Gland Disorders Treatment Market?

The base year of this report is 2015.

Who are the major players in this market?

Abbott Laboratories, Abbvie, Inc.,Allergan plc.,Glaxo SmithKline plc, are some of the major players in the global market.

OTC Vitamins Dietary Supplements Market

Published:
Report ID: 35994

US Retail Pharmacy Market

Published:
Report ID: 32801

Liposomes Market

Published:
Report ID: 35888

UK Iron Supplement Market

Published:
Report ID: 35709

U.S. Iron Supplement Market

Published:
Report ID: 35688

Malignant Ascites Market

Published:
Report ID: 11184

Middle East and Africa In-Vitro Fertilization (IVF) Market

Published:
Report ID: 35578

Chronic Myeloid Leukemia (CML) Treatment Market

Published:
Report ID: 2939

Combination Therapies In Aesthetics Market

Published:
Report ID: 35434

CAR T-Cell Therapy Market

Published:
Report ID: 2051

OTC Cough Cold And Allergy Medicine Market

Published:
Report ID: 20062

Heart Health Supplements Market

Published:
Report ID: 6184

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN